Tehran University of Medical Sciences, Tehran, Iran.
Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran.
J Cosmet Dermatol. 2020 May;19(5):1093-1098. doi: 10.1111/jocd.13369. Epub 2020 Mar 20.
Melasma is a difficult to treat pigmentation disorder. However, some successes have been attained by microneedling. The aim of the present study was to evaluate the efficacy of microneedling using meso-depigmentation solution (mesoneedling) in comparison with standard microneedling, over a 4-month treatment period.
As a part of this pilot study, 20 patients received microneedling on one side and mesoneedling on another side of their face. Treatment was repeated on a monthly basis for 4 months. Treatment efficacy was defined through Dermacatch colorimetry, modified Melasma Area and Severity (mMASI) score determination, Investigator's Global Assessment (IGA), and patient questionnaires, whereby all assessments were conducted at the baseline, as well after 2 and 4 months of treatment.
Before treatments, mean difference between pigmented and normal skin calculated by Dermacatch was 43.7 ± 20.12 and 44.6 ± 20.72 in microneedling sides and mesoneedling sides, respectively. After two and four sessions, these values declined to 34.5 ± 16.26 and 28.05 ± 13.79 on the side subjected to microneedling, while 29.75 ± 15.07 and 20.45 ± 10.58 were measured on the mesoneedling side. Statistically significant differences have been observed between microneedling and mesoneedling treatments at both time points (P = .0001, P = .0001). The mMASI scores obtained upon treatment completion were significantly lower on both the microneedling and the mesoneedling side. The IGA and patients' self-assessment scores further confirmed that both treatments were effective in treating melasma, without producing any notable side-effects or complications.
In sum, both microneedling and mesoneedling are effective in decreasing melanin content in the epidermal melasma lesions.
黄褐斑是一种难以治疗的色素沉着障碍。然而,微针治疗已取得一些成效。本研究的目的是评估中胚层脱色溶液(mesoneedling)联合微针治疗相较于标准微针治疗在 4 个月治疗期间的疗效。
作为这项初步研究的一部分,20 名患者接受了一侧微针治疗和另一侧 mesoneedling 治疗。每月重复治疗,共治疗 4 个月。通过 Dermacatch 比色法、改良黄褐斑面积和严重程度评分(mMASI)、研究者整体评估(IGA)和患者问卷调查来定义治疗效果,所有评估均在基线时、治疗后 2 个月和 4 个月时进行。
在治疗前,通过 Dermacatch 计算的色素沉着和正常皮肤之间的平均差异在微针治疗侧和 mesoneedling 侧分别为 43.7±20.12 和 44.6±20.72。在经过两次和四次治疗后,微针治疗侧的值下降至 34.5±16.26 和 28.05±13.79,而 mesoneedling 侧的值为 29.75±15.07 和 20.45±10.58。在这两个时间点,微针治疗和 mesoneedling 治疗之间的差异均具有统计学意义(P=0.0001,P=0.0001)。治疗完成后,mMASI 评分在微针治疗和 mesoneedling 侧均显著降低。IGA 和患者自我评估评分进一步证实,两种治疗方法均能有效治疗黄褐斑,且无明显的副作用或并发症。
总之,微针和 mesoneedling 均可有效降低表皮黄褐斑皮损中的黑色素含量。